CCL Products Q1 FY27 Earnings Call Transcript Released
CCL Products reported Q1 FY27 turnover of ₹1,203.59 crore, up 13.76%, with EBITDA at ₹196.69 crore and net profit at ₹116.87 crore. The company maintained its 15% volume growth guidance despite a 20% Q1 achievement. Debt reduced to ₹963 crore by June 2026. Domestic branded business targets ₹550-600 crore for FY27.
The announcement provides an update on Q1 FY27 results and a conference call transcript, which are routine for listed companies. While the results are positive, they do not indicate a major strategic shift or a significant one-time event that would warrant a 'HIGH' impact. The information is valuable for investors tracking the company's performance.
The company reported strong year-on-year growth in turnover, EBITDA, and net profit for Q1 FY27. Significant deleveraging of the balance sheet and positive traction in the domestic branded business and international B2C segment contribute to a positive sentiment.
CCL Products (India) Limited has released the transcript of its conference call held on July 28, 2026, to discuss the results for the first quarter of the financial year 2026-27. The company reported a turnover of ₹1,203.59 crore for Q1 FY27, a growth of 13.76% over the previous year, driven by a nearly 20% volume growth. EBITDA increased by 21.84% to ₹196.69 crore, while net profit surged by 61.31% to ₹116.87 crore.
The company's CFO highlighted that FY26 was an inflection point, with top-line growth of 43.5% to ₹4,457 crore and PAT growth of 25% to ₹388 crore. Significant deleveraging occurred, reducing debt from a peak of ₹1,950 crore in December 2024 to ₹1,268 crore by March 2026, with net debt further decreasing to ₹963 crore by June 2026. This was achieved through operational efficiencies and a focus on working capital, without equity dilution.
During the Q&A, management reiterated a commitment to 15% volume growth guidance, despite achieving 20% in Q1 FY27, citing market volatility. They confirmed the company is naturally hedged regarding currency fluctuations. Capacity utilization is between 65-70%, with higher utilization for freeze-dried coffee. Capex plans for FY27 are modest, between ₹25-50 crore, focusing on upgrades rather than major expansions for the next 2-3 years. The branded domestic business is projected to reach ₹550-600 crore in FY27, with market share gains in South India and modern trade channels. The international B2C business, including Percol in the UK, is showing positive traction, with plans to expand into the US and Middle East markets.
What to do with a filing like this
CCL Products (India) Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CCL Products (India) Limited. Read the original for the full detail.